ARIX BIOSCIENCE PLC financials
ARIX BIOSCIENCE PLC
213800OVT3AHQCXNIX43 | Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | £112.0K | £340.0K |
| Administrative expenses | £5.4M | £5.1M |
| Employee benefits expense | £0 | -£266.0K |
| Operating profit (EBIT) | -£29.2M | -£60.1M |
| Profit before tax | -£27.6M | -£61.1M |
| Income tax expense | -£4.0K | £0 |
| Profit for the year | -£27.6M | -£61.1M |
| Total comprehensive income | -£29.6M | -£61.0M |
| Per share | ||
| Basic EPS | £-0.24 | £-0.48 |
| Free cash flow / share | £-0.04 | £-0.06 |
| Cash flow statement | ||
| Cash generated from operations | -£6.2M | -£7.3M |
| Net cash from operating activities | -£4.6M | -£7.1M |
| Net cash from investing activities | -£12.8M | £42.0M |
| Purchase of PP&E (capex) | £8.0K | £101.0K |
| Net cash from financing activities | -£63.0K | -£11.6M |
| Lease liability payments | £63.0K | £0 |
| Net change in cash | -£17.5M | £23.3M |
| Balance sheet | ||
| Total assets | £227.8M | £257.1M |
| Non-current assets | £102.8M | £121.0M |
| Property, plant & equipment | £57.0K | £85.0K |
| Right-of-use assets | £72.0K | £121.0K |
| Intangible assets & goodwill | £24.0K | £168.0K |
| Current assets | £125.0M | £136.1M |
| Cash & equivalents | £122.8M | £134.2M |
| Total equity | £225.9M | £255.4M |
| Lease liabilities (non-current) | £11.0K | £121.0K |
| Current liabilities | £1.9M | £1.6M |
| Lease liabilities (current) | £59.0K | £0 |
| Trade & other payables | £1.9M | £1.6M |
| Derived metrics | ||
| Free cash flow | -£4.6M | -£7.2M |
| Operating margin | -26035.7% | -17687.4% |
| Net margin | -24620.5% | -17965.9% |
| Return on equity | -12.2% | -23.9% |
| Cash conversion ratio | 0.17× | 0.12× |
| Capex coverage | -579.50× | -70.67× |
| Other reported items | ||
| Comprehensive Income Attributable To Owners of Parent | -£29.6M | -£61.0M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | £6.1M | -£1.2M |
| Finance Costs Paid Classified As Operating Activities | £1.0K | £0 |
| Finance Income | £1.6M | £156.0K |
| Finance Income Received Classified As Operating Activities | £1.6M | £156.0K |
| Foreign Exchange Loss | £0 | £1.4M |
| Gains Losses On Exchange Differences On Translation Before Tax | -£2.0M | £91.0K |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | £6.9M | £0 |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | £0 | £0 |
| Income Taxes Paid Refund Classified As Operating Activities | -£4.0K | £0 |
| Increase Decrease Through Sharebased Payment Transactions | £181.0K | -£266.0K |
| Investment Accounted For Using Equity Method | £102.7M | £120.6M |
| Issue of Equity | — | £0 |
| Liabilities | £1.9M | £1.7M |
| Net Assets Liabilities | £225.9M | £255.4M |
| Other Cash Payments To Acquire Equity Or Debt Instruments of Other Entities Classified As Investing Activities | £33.6M | £59.2M |
| Other Cash Receipts From Sales of Equity Or Debt Instruments of Other Entities Classified As Investing Activities | £20.8M | £39.1M |
| Other Comprehensive Income | -£2.0M | £91.0K |
| Other Current Assets | £2.2M | £1.8M |
| Other Reserves | -£13.9M | -£13.9M |
| Payments To Acquire Or Redeem Entitys Shares | £0 | £11.6M |
| Purchase of Treasury Shares | — | £11.6M |
| Retained Earnings | £51.3M | £80.7M |
Every line item above is a fact tagged in ARIX BIOSCIENCE PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.